Replies to post #861 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

In 2004, GTC licensed its IP to Nexia for the biodefense product, Protexia (#msg-4107224). Protexia is now owned by PharmAthene (who since merged with SIGA: #msg-11540838).

GTC could some day realize a small royalty stream from this.